Some names in the Dow Jones Industrial Average could continue their gains next year, according to Wall Street analysts. This year, the 30-stock Dow is up nearly 15%. But the index has lost more than 3% this month, putting it on track for its worst month since April. However, companies such as Nvidia and Merck may reliably buck a slump and come out on top next year, according to analysts.
' name in the category" with continued great performance from Keytruda. stands for "growth at a reasonable price." Anderson is not as bullish on Johnson & Johnson and Amgen , however, giving them neutral and underperform ratings, respectively. Both of these names made it to CNBC's screen. Amgen's "obesity premium" appears to be coming out of the stock but there could still be more room to run, Anderson said in a Dec. 10 note. Pockets of Wall Street are still bullish on those pharma stocks after a rough year for the group, however.